1. Methods for the diagnosis and treatment of pulmonary fibrosis in subjects with Hermansky Pudlak Syndrome comprising IL-13Rα2 agonist or CRTH2 inhibitor in relation to elevated levels of CHI3L1

By: Elias, Jack A.; Zhou, Yang; Lee, Chun Geun

Assignee: Brown University, USA; Yale University

Patent Information: Oct 29, 2015, WO 2015164716, A1

Application: Apr 24, 2015, WO 2015-US27481

Priority: Apr 25, 2014, US 2014-61984253, Nov 19, 2014, US 2014-62081701

Source: PCT Int. Appl., 101pp., Patent, 2015, CODEN: PIXXD2

Accession Number: 2015:1726683, CAN 163:628860, CAPLUS

Language: English

Abstract

Described herein are methods, assays, and systems related to the prognosis, diagnosis, and treatment of Hermansky Pudlak Syndrome (HPS) and, e.g., pulmonary fibrosis in a subject. As described herein, subjects with HPS who have, will develop, or are most at risk or developing pulmonary fibrosis have elevated levels of CHI3L1. In some embodiments, the methods comprise administering an agonist of IL-13Rα2 or an inhibitor of CRTH2 to the subject.



Fig. 5A

Patent Information

Patent No.	Kind	Date	Application No.	Date
WO 2015164716	A1	Oct 29, 2015	WO 2015-US27481	Apr 24, 2015

Priority Application

US 2014-61984253	P	Apr 25, 2014
US 2014-62081701	P	Nov 19, 2014

Indexing

Pharmacology (Section 1-9)
Section cross-reference(s):14

Supplementary Terms

pulmonary fibrosis diagnosis treatment CHI3L1 IL13Ralpha2 agonist CRTH2 inhibitor

Citations

1)ABBAS ALEXANDER R; WO 2013148232 A1 2013

2)Anon; LUMSDEN ET AL.: "Overexpression Of IL -13Ra2 In The Mouse Lung Inhibits Induction Of Fibrotic Markers In Bleomycin Induced Pulmonary Fibrosis.", AM J RESPIR CRIT CARE MED, CONFERENCE ABSTRACT, 2013, Retrieved from the Internet <URL:http://www.atsjoumals.or

3)Anon; ZHOU ET AL.: "Chitinase 3-Like 1 (CHI3L1) As A Biomarker And Therapeutic Target In The Pulmonary Fibrosis Of Hermansky-Pudlak Syndrome.", AM J RESPIR CRIT CARE MED, MEETING ABSTRACT, 2012, Retrieved from the Internet <URL:http://www.atsjoumals.org/doi/abs/

4)DE PERROT MARC; US 20130029873 A1 2013

2. Dermal formulations of prostaglandin D2 (DP2) receptor antagonists

By: Hutchinson, John Howard

Assignee: Amira Pharmaceuticals, Inc., USA

Patent Information: Feb 03, 2011, WO 2011014588, A2

Application: Jul 28, 2010, WO 2010-US43599

Priority: Jul 31, 2009, US 2009-61230585, Jul 28, 2010, WO 2010-US43599

Source: PCT Int. Appl., 59pp., Patent, 2011, CODEN: PIXXD2

Accession Number: 2011:145454, CAN 154:243925, CAPLUS

Language: English

Abstract

Described are topical formulations for use in the treatment or prevention of dermatol. diseases, disorders, or conditions in a mammal. Also pharmacol. examples are given including DP_2/CRTH2 binding assays, DP_1 binding assays, and rabbit wound healing and hypertrophic scar model.



Patent Information

Patent No.	Kind	Date	Application No.	Date
WO 2011014588	A2	Feb 03, 2011	WO 2010-US43599	Jul 28, 2010
WO 2011014588	A3	Jun 23, 2011		
CA 2768586	A1	Feb 03, 2011	CA 2010-2768586	Jul 28, 2010
KR 2012046762	A	May 10, 2012	KR 2012-7005366	Jul 28, 2010
CN 102596193	A	Jul 18, 2012	CN 2010-80034188	Jul 28, 2010
EP 2480225	A2	Aug 01, 2012	EP 2010-805005	Jul 28, 2010
JP 2013500979	T	Jan 10, 2013	JP 2012-523016	Jul 28, 2010
IL 217588	A	Feb 28, 2013	IL 2010-217588	Jul 28, 2010
AR 77435	A1	Aug 24, 2011	AR 2010-102809	Jul 30, 2010

TW I428315	B	Mar 01, 2014	TW 2010-125502	Jul 30, 2010
US 20120184493	A1	Jul 19, 2012	US 2012-13387047	Apr 02, 2012

Priority Application

US 2009-61230585	P	Jul 31, 2009
WO 2010-US43599	W	Jul 28, 2010

Indexing

Pharmaceuticals (Section 63-6)
Section cross-reference(s):1, 2

Supplementary Terms

dermal formulation prostaglandin D2 receptor antagonist